BRANFORD, Conn., May 4, 2010 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that six abstracts featuring the use of the FORE-SIGHT ® Absolute Oximeter were presented at the Pediatric Academic Societies meeting May 1-4 in Vancouver, BC, Canada. This meeting includes more than 7,500 leaders in academic pediatrics and is dedicated to the advancement of pediatric research and the advanced care of acutely ill children. Several studies presented demonstrate the clinical efficacy of using the FORE-SIGHT system to monitor gastrointestinal tissue oxygen saturation. This is significant in that the gastrointestinal system of pre-term infants may not be mature, making the babies predisposed to nectrotizing enterocolitis (NEC), gastric perforation, and volvulus. Measurement of tissue oxygenation can aid in the evaluation of bowel motility, intestinal blood flow, and compensation for the presence of meconium. In addition, a study was presented on the accuracy of monitoring the oxygenation of liver tissue in a piglet model, which approximates a small human newborn. It should be noted that these non-cerebral applications for the FORE-SIGHT system are pending FDA 510(k) clearance. Further studies show the use of FORE-SIGHT in various neonatal applications, including monitoring the affects of therapeutic hypothermia on cerebral circulation and monitoring brain oxygenation during periods of peripheral hyper- or hypoxemia. Andrew E. Kersey, President & CEO of CASMED, commented, "The presentation of these clinical abstracts at this important medical academic meeting demonstrate the value of FORE-SIGHT Absolute Oximetry technology to the care of neonatal patients. These findings are from some of the leading international centers for the care of the very sickest newborns. We are pleased with these additions to our portfolio of clinical evidence supporting the FORE-SIGHT system, and look forward to additional studies being released in the near future." About CASMED ® - Monitoring What's Vital CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.